Calcitonin gene‐related peptide inhibits angiotensin II‐induced NADPH oxidase‐dependent ROS via the Src/STAT3 signalling pathway

Luo, Hongmin; Wu, Xia; Xian, Xian; Wang, Lu-Yao; Zhu, Lan; Sun, Haixia; Yang, Lei; Liu, Wenxuan

doi:10.1111/jcmm.15288

Cited by 15 publications

(11 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the CGRP has been involved in antioxidant activation, both in vivo and in vitro, other than in nociception [ 18 , 19 , 24 , 25 , 26 ]. In this scenario, we were not able to define which role is played exclusively by the CGRP-signaling blockage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Luca

Baldacci

Mazzucchi

et al. 2021

JCM

View full text Add to dashboard Cite

Patients with high-frequency resistant migraine and medication-overuse headache are still the main clinical challenge in tertiary headache centers. The approval of targeted antibodies against the calcitonin gene-related peptide (CGRP) and its receptor represents a powerful instrument. In this study, we observed how biological and clinical features of resistant migraineurs responded to erenumab, fremanezumab, or galcanezumab. We found a reduction in advanced oxidation protein products (AOPP) as a biomarker of improved redox state after six months of treatment. We also found that treatment efficacy was precocious and maintained with high individual responder rates. In particular, seven out of ten patients achieved a reduction of 50% from the baseline at three months, which was maintained at six months, while about one out of our patients experienced a 75% reduction in headache frequency from the first month of treatment. The migraine disability assessment (MIDAS) and the associated fatigue, anxiety, and sleep quality also significantly improved. The allodynia symptom dropped from moderate/severe to mild/absent as a sign of central sensitization reduction. Our study confirmed the safety and efficacy of CGRP inhibition in real-life, high-challenging patients. Additional evidence is needed to understand the role of oxidative stress as a migraine biomarker.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The exact mechanisms of BoNT/A effectiveness in chronic migraine prophylaxis are not clear; however, lower peripheral plasmatic levels of CGRP have been reported after BoNT/A treatment [ 16 ]. However, aside from nociception, CGRP plays a role in oxidative stress, as reported by recent studies [ 17 , 18 , 19 ].…”

Section: Introductionmentioning

confidence: 96%

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Luca

Baldacci

Mazzucchi

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…Orientin inhibits H2O2-induced apoptosis of PC12 cells by inhibiting ROS-mediated Src-MAPK/AKT signal transduction [ 88 ]. Src mediates the activation of STAT3 in vascular smooth muscle cells stimulated by Ang II, which increases ROS production and induces oxidative stress [ 89 ].…”

Section: The Pathophysiological Role Of Sfks In Akimentioning

confidence: 99%

Src Family Kinases: A Potential Therapeutic Target for Acute Kidney Injury

Lin

Zhang

et al. 2022

Biomolecules

View full text Add to dashboard Cite

Src family kinases (SFKs) are non-receptor tyrosine kinases and play a key role in regulating signal transduction. The mechanism of SFKs in various tumors has been widely studied, and there are more and more studies on its role in the kidney. Acute kidney injury (AKI) is a disease with complex pathogenesis, including oxidative stress (OS), inflammation, endoplasmic reticulum (ER) stress, autophagy, and apoptosis. In addition, fibrosis has a significant impact on the progression of AKI to developing chronic kidney disease (CKD). The mortality rate of this disease is very high, and there is no effective treatment drug at present. In recent years, some studies have found that SFKs, especially Src, Fyn, and Lyn, are involved in the pathogenesis of AKI. In this paper, the structure, function, and role of SFKs in AKI are discussed. SFKs play a crucial role in the occurrence and development of AKI, making them promising molecular targets for the treatment of AKI.

show abstract

“…Oxidative stress was reported to promote the migration, invasion, and metastasis of NSCLC through the LATS2/YAP signaling pathway in a recent study [ 101 ]. Reactive oxygen species (ROS) are the downstream products of oxidative stress and have been identified to be involved in response to anti-cancer therapies in human NSCLC [ 102 , 103 ]. A previous study by Huang et al reported that the activation of YAP increased the accumulation of ROS by downregulating the antioxidant enzyme GPX2 in human lung squamous cell carcinoma [ 104 ].…”

Section: Hippo/yap Singing Pathway In Nsclcmentioning

confidence: 99%

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

Hsu

Yang

Jablons

et al. 2020

Cancers

View full text Add to dashboard Cite

The advancement of new therapies, including targeted therapies and immunotherapies, has improved the survival of non-small-cell lung cancer (NSCLC) patients in the last decade. Some NSCLC patients still do not benefit from therapies or encounter progressive disease during the course of treatment because they have intrinsic resistance, acquired resistance, or lack a targetable driver mutation. More investigations on the molecular biology of NSCLC are needed to find useful biomarkers for current therapies and to develop novel therapeutic strategies. Src is a non-receptor tyrosine kinase protein that interacts with cell surface growth factor receptors and the intracellular signaling pathway to maintain cell survival tumorigenesis in NSCLC. The Yes-associated protein (YAP) is one of the main effectors of the Hippo pathway and has been identified as a promoter of drug resistance, cancer progression, and metastasis in NSCLC. Here, we review studies that have investigated the activation of YAP as mediated by Src kinases and demonstrate that Src regulates YAP through three main mechanisms: (1) direct phosphorylation; (2) the activation of pathways repressing Hippo kinases; and (3) Hippo-independent mechanisms. Further work should focus on the efficacy of Src inhibitors in inhibiting YAP activity in NSCLC. In addition, future efforts toward developing potentially reasonable combinations of therapy targeting the Src–YAP axis using other therapies, including targeted therapies and/or immunotherapies, are warranted.

show abstract

Calcitonin gene‐related peptide inhibits angiotensin II‐induced NADPH oxidase‐dependent ROS via the Src/STAT3 signalling pathway

Cited by 15 publications

References 37 publications

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

Src Family Kinases: A Potential Therapeutic Target for Acute Kidney Injury

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)

Contact Info

Product

Resources

About